Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

New Christie Assure Program Revolutionizes VeinViewer Utilization Services at Hospitals across America



  New Christie Assure Program Revolutionizes VeinViewer Utilization Services
  at Hospitals across America

Five-year program expected to lead industry in utilization training, clinical
                       education and warranty offerings

Business Wire

MEMPHIS, Tenn. -- July 18, 2013

Christie Medical Holdings, Inc. today launched a nationwide, industry-leading
program for U.S. acute hospitals that use the HD VeinViewer® vein illumination
products designed to project vascular imaging on the surface of the skin.
Making up the Christie Assure program is a comprehensive set of services
including a five-year utilization training program, five-year warranty,
five-year clinical education provision for hospital medical staff and
five-year upgrade program to the latest product platforms from Christie. An
industry-first, the Christie Assure Program represents a significant
leadership investment in seeing the end customer achieve utilization and
results through Christie technologies.

Chris Schnee, general manager and vice president of sales and marketing at
Christie Medical Holdings, said, “Our extensive multi-year Assure Program is a
first in the vascular imaging device industry. Each element of this new
program not only demonstrates Christie’s confidence and leadership in the
technology itself, but unmatched support and training for hospital staff who
use VeinViewer, striving to help them achieve an increase in patient
satisfaction scores, potential reduction in patient risk and infection, and
maximized health care economic benefits at their hospitals.”

The Christie Assure program was built by executing a thorough Voice of
Customer survey and addressing customer priorities. Customers told Christie
they wanted the company to help them achieve the same results proven in
multiple clinical studies. They also wanted to have the confidence that the
company standing behind the technology is committed for the long term. Schnee
continued: “Through Christie Assure, we achieve customer support at a higher
level than I have seen anywhere previously in my career.”

The Christie Assure Program:

5-Year Utilization Training Beyond “Button Pushing” After Delivery of Device

Hands-on Utilization Training is taught by Clinical Applications Consultants
(CACs), nurses skilled in venipuncture procedures, IV policy, procedure
development and hospital-wide device implementation. The program offers
in-depth training to hospital staff to bolster the VeinViewer integration;
using the skills nurses already possess to achieve measurable results.

Clinical studies have proven the benefits of VeinViewer technology with
results showing up to a 100 percent increase in first stick success rates, up
to a 100 percent increase in patient satisfaction ratings and a 50 percent
decrease in medically unnecessary PICC lines. The goal is to maximize the
positive return each facility receives from its investment and to improve
patient care.

5-Year Clinical Education Surpasses Typical “In-Service” Support

The five-year clinical education component offered under the Christie Assure
Program includes VeinViewer implementation that surpasses the “in-service”
support that typically accompanies the sale of products. The Clinical
Education program offers both product education and implementation managed and
delivered by a CAC. The program teaches advanced concepts of using VeinViewer,
proper techniques for visualization, critical thinking skills and scenarios –
all to help improve overall vascular access and protocol adoption. Clinical
assessment of the IV site is key and VeinViewer is the only device of its kind
to provide Pre, During and Post-access (PDP) vascular visualization benefits,
elevating it from a simple vein finder to providing exclusive HD imaging
quality benefits. Training beyond the initial needlestick and even beyond the
first IV placement is critical to full utilization and benefiting patient care
and patient care economics. Through this program, VeinViewer users stay
current on the latest innovations in medical devices, such as near-infrared
technologies in peripheral vascular access, and guidance from key industry
bodies that set national standards.

5-Year Warranty and Upgrade Path Eliminates Ongoing Total Cost of Ownership
concerns

Christie’s Assure Program includes a full five-year parts and labor warranty
program for all VeinViewers purchased starting June 2013, and includes a
five-year technology upgrade path for existing customers who wish to upgrade
their current technology or trade-in other manufacturers’ technology through
the popular FreshStart program. “Removing the concern of mounting costs in
future years, the need to buy service agreements and worries over providing
customer loyalty pathways to future technologies were key customer requests,”
added Chris Schnee.

Customers should review the Christie Assure Program in detail for relevant
terms that apply.

VeinViewer technology backed by Christie’s long history of technical
achievements

VeinViewer technology was developed with aid of the engineering capabilities
and resources of parent company Christie Digital Systems, a leading global
visual technology firm with more than 80 years of experience in the projection
systems industry. VeinViewer is the first and only device on the market to
use: harmless near-infrared light, DLP® technologies, exclusive technology
such as Active Vascular Imaging Navigation (AVIN™) providing the demanded Pre,
During and Post-access (PDP) benefits, TrueView imaging accuracy in projected
vein-widths which is three to ten times more accurate than competition, and
technologies such as DF^2 (Digital Full Field) to illuminate the only
real-time HD digital image of subcutaneous vasculature and blood patterns
directly onto the skin surface . Although designed for assistance in IV starts
and blood draws, VeinViewer has proven beneficial in spider and varicose vein
treatment.

To learn more about Christie  product offerings: VeinViewer Vision, VeinViewer
Vision^XTND and VeinViewer Flex, please visit www.veinviewer.com.

About Christie Medical Holdings, Inc.

Christie Medical Holdings Inc. is a global company based in Memphis, Tenn.,
that discovers, develops and commercializes medical technologies. The
company’s market-leading product, VeinViewer^®, is a mobile vascular imaging
system that allows health care providers to clearly see accessible vasculature
as a real time HD image, directly on the surface of the skin. Christie Medical
Holdings Inc. is owned by Christie Digital Systems Inc., a global visual
technologies company and a subsidiary of Ushio Inc., Japan (JP:6925). For more
information on Christie Digital Systems or Christie Medical Holdings, visit
www.christiedigital.com

Follow us on Twitter @veinviewer

DLP® is a registered trademark of Texas Instruments.

Contact:

Christie Medical Holdings, Inc.
Carmen Robert, 519-572-5824
carmen.robert@christiedigital.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement